Cargando…
LGG-15. Late mortality and morbidity of adult survivors of childhood glioma treated across three decades: a report from the Childhood Cancer Survivor Study
PURPOSE: Pediatric low-grade glioma therapy has evolved to delay or eliminate radiation. The impact of therapy changes on long-term outcomes remains unknown. METHODS: Cumulative incidence of late mortality (death >5 years from diagnosis), subsequent neoplasms (SNs), and chronic health conditions...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164667/ http://dx.doi.org/10.1093/neuonc/noac079.330 |
_version_ | 1784720189200269312 |
---|---|
author | de Blank, Peter M K Lange, Katharine R Xing, Mengqi Salehabadi, Sedigheh Mirzaei Srivatava, Deokumar Brinkman, Tara M Ness, Kirsten K Oeffinger, Kevin C Neglia, Joseph Krull, Kevin R Yasui, Yutaka Nathan, Paul Howell, Rebecca Turcotte, Lucie Leisenring, Wendy Armstrong, Gregory T Bowers, Daniel C Okcu, M Fatih |
author_facet | de Blank, Peter M K Lange, Katharine R Xing, Mengqi Salehabadi, Sedigheh Mirzaei Srivatava, Deokumar Brinkman, Tara M Ness, Kirsten K Oeffinger, Kevin C Neglia, Joseph Krull, Kevin R Yasui, Yutaka Nathan, Paul Howell, Rebecca Turcotte, Lucie Leisenring, Wendy Armstrong, Gregory T Bowers, Daniel C Okcu, M Fatih |
author_sort | de Blank, Peter M K |
collection | PubMed |
description | PURPOSE: Pediatric low-grade glioma therapy has evolved to delay or eliminate radiation. The impact of therapy changes on long-term outcomes remains unknown. METHODS: Cumulative incidence of late mortality (death >5 years from diagnosis), subsequent neoplasms (SNs), and chronic health conditions (CHCs, CTCAE grading criteria) were evaluated in the Childhood Cancer Survivor Study among 5-year survivors of glioma diagnosed 1970-1999. Outcomes were evaluated by diagnosis decade and by treatment exposures received ≤5 years following diagnosis (surgery-only, chemotherapy ± surgery, and cranial radiation ± surgery or chemotherapy). Relative risk (RRs) with 95%CIs estimated long-term outcomes using multivariable piecewise exponential models. RESULTS: Among 2,684 eligible survivors (age at diagnosis (median [range]), 7 years [0-20 years]; time from diagnosis, 24 years [5-48 years]), exposure to cranial radiation decreased [51% (1970s), 45% (1980s), 25% (1990s)] along with late tumor recurrence (>5 & ≤15 years from diagnosis) [9.8% (1970s), 8.8% (1980s), 5.0% (1990s)]. The 15-year cumulative incidence of late mortality was 10.3% (1970s), 6.5% (1980s), and 6.0% (1990s) (p<0.001, comparison of cumulative incidence curves). The 15-year cumulative incidence of grade 3-5 CHCs was 19.7% (1970s), 17.8% (1980s), and 14.2% (1990s) (p<0.0001). A reduction in SN incidence was not observed. In multivariable analyses excluding treatment exposure, later diagnosis (1990s vs. 1970s) was associated with lower risk of late mortality, grade 3-5 CHCs and SNs. Inclusion of treatment exposure in the model attenuated the effect of diagnosis decade. Radiation or chemotherapy exposure increased risk compared to surgery alone for late mortality (radiation RR 4.95, 95%CI 3.79-6.47; chemotherapy RR 2.88, 95%CI 1.85-4.48), CHCs (radiation RR 4.02, 95%CI 3.28-4.94; chemotherapy RR 1.66, 95%CI 1.13-2.45), and SNs (radiation RR 4.02, 95%CI 3.06-6.13, chemotherapy RR 2.08, 95%CI 1.03-4.23)). CONCLUSION: Late mortality and CHCs decreased in childhood glioma survivors diagnosed from 1970-1999 largely due to therapy changes, particularly avoidance of cranial radiation, without increased late recurrence. |
format | Online Article Text |
id | pubmed-9164667 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-91646672022-06-05 LGG-15. Late mortality and morbidity of adult survivors of childhood glioma treated across three decades: a report from the Childhood Cancer Survivor Study de Blank, Peter M K Lange, Katharine R Xing, Mengqi Salehabadi, Sedigheh Mirzaei Srivatava, Deokumar Brinkman, Tara M Ness, Kirsten K Oeffinger, Kevin C Neglia, Joseph Krull, Kevin R Yasui, Yutaka Nathan, Paul Howell, Rebecca Turcotte, Lucie Leisenring, Wendy Armstrong, Gregory T Bowers, Daniel C Okcu, M Fatih Neuro Oncol Low Grade Glioma PURPOSE: Pediatric low-grade glioma therapy has evolved to delay or eliminate radiation. The impact of therapy changes on long-term outcomes remains unknown. METHODS: Cumulative incidence of late mortality (death >5 years from diagnosis), subsequent neoplasms (SNs), and chronic health conditions (CHCs, CTCAE grading criteria) were evaluated in the Childhood Cancer Survivor Study among 5-year survivors of glioma diagnosed 1970-1999. Outcomes were evaluated by diagnosis decade and by treatment exposures received ≤5 years following diagnosis (surgery-only, chemotherapy ± surgery, and cranial radiation ± surgery or chemotherapy). Relative risk (RRs) with 95%CIs estimated long-term outcomes using multivariable piecewise exponential models. RESULTS: Among 2,684 eligible survivors (age at diagnosis (median [range]), 7 years [0-20 years]; time from diagnosis, 24 years [5-48 years]), exposure to cranial radiation decreased [51% (1970s), 45% (1980s), 25% (1990s)] along with late tumor recurrence (>5 & ≤15 years from diagnosis) [9.8% (1970s), 8.8% (1980s), 5.0% (1990s)]. The 15-year cumulative incidence of late mortality was 10.3% (1970s), 6.5% (1980s), and 6.0% (1990s) (p<0.001, comparison of cumulative incidence curves). The 15-year cumulative incidence of grade 3-5 CHCs was 19.7% (1970s), 17.8% (1980s), and 14.2% (1990s) (p<0.0001). A reduction in SN incidence was not observed. In multivariable analyses excluding treatment exposure, later diagnosis (1990s vs. 1970s) was associated with lower risk of late mortality, grade 3-5 CHCs and SNs. Inclusion of treatment exposure in the model attenuated the effect of diagnosis decade. Radiation or chemotherapy exposure increased risk compared to surgery alone for late mortality (radiation RR 4.95, 95%CI 3.79-6.47; chemotherapy RR 2.88, 95%CI 1.85-4.48), CHCs (radiation RR 4.02, 95%CI 3.28-4.94; chemotherapy RR 1.66, 95%CI 1.13-2.45), and SNs (radiation RR 4.02, 95%CI 3.06-6.13, chemotherapy RR 2.08, 95%CI 1.03-4.23)). CONCLUSION: Late mortality and CHCs decreased in childhood glioma survivors diagnosed from 1970-1999 largely due to therapy changes, particularly avoidance of cranial radiation, without increased late recurrence. Oxford University Press 2022-06-03 /pmc/articles/PMC9164667/ http://dx.doi.org/10.1093/neuonc/noac079.330 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Low Grade Glioma de Blank, Peter M K Lange, Katharine R Xing, Mengqi Salehabadi, Sedigheh Mirzaei Srivatava, Deokumar Brinkman, Tara M Ness, Kirsten K Oeffinger, Kevin C Neglia, Joseph Krull, Kevin R Yasui, Yutaka Nathan, Paul Howell, Rebecca Turcotte, Lucie Leisenring, Wendy Armstrong, Gregory T Bowers, Daniel C Okcu, M Fatih LGG-15. Late mortality and morbidity of adult survivors of childhood glioma treated across three decades: a report from the Childhood Cancer Survivor Study |
title | LGG-15. Late mortality and morbidity of adult survivors of childhood glioma treated across three decades: a report from the Childhood Cancer Survivor Study |
title_full | LGG-15. Late mortality and morbidity of adult survivors of childhood glioma treated across three decades: a report from the Childhood Cancer Survivor Study |
title_fullStr | LGG-15. Late mortality and morbidity of adult survivors of childhood glioma treated across three decades: a report from the Childhood Cancer Survivor Study |
title_full_unstemmed | LGG-15. Late mortality and morbidity of adult survivors of childhood glioma treated across three decades: a report from the Childhood Cancer Survivor Study |
title_short | LGG-15. Late mortality and morbidity of adult survivors of childhood glioma treated across three decades: a report from the Childhood Cancer Survivor Study |
title_sort | lgg-15. late mortality and morbidity of adult survivors of childhood glioma treated across three decades: a report from the childhood cancer survivor study |
topic | Low Grade Glioma |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164667/ http://dx.doi.org/10.1093/neuonc/noac079.330 |
work_keys_str_mv | AT deblankpetermk lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy AT langekathariner lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy AT xingmengqi lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy AT salehabadisedighehmirzaei lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy AT srivatavadeokumar lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy AT brinkmantaram lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy AT nesskirstenk lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy AT oeffingerkevinc lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy AT negliajoseph lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy AT krullkevinr lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy AT yasuiyutaka lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy AT nathanpaul lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy AT howellrebecca lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy AT turcottelucie lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy AT leisenringwendy lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy AT armstronggregoryt lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy AT bowersdanielc lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy AT okcumfatih lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy |